The former chief executive of licensed producer CanniMed Therapeutics Inc. has a budding new cannabis business largely made up of his former employees — but his newest venture won’t involve growing pot. Biopharmaceutical company Zyus Life Sciences Inc. will instead buy cannabis from licensed producers and focus on extraction and development of plant-based medicinal products for the global medical market, said former CanniMed CEO Brent Zettl. Instead of growing pot, former CanniMed CEO Brent Zettl says his biopharmaceutical company Zyus Life Sciences Inc. will instead buy cannabis from licensed producers and focus on extraction and development of plant-based medicinal products for the global medical market. Last January, Edmonton-based licensed producer Aurora Cannabis struck a stock-and-cash deal valued at $1.1 billion to buy CanniMed. Zettl sees this new company as a continuation of the work he and his team began at CanniMed.

Source: thestar January 07, 2019 17:03 UTC